Antero Midstream Corporation — News

While the top- and bottom-line numbers for Antero Midstream (AM) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

zacks.com - 2026-07-29 19:31:07

DENVER, July 29, 2026 /PRNewswire/ -- Antero Midstream Corporation (NYSE: AM) ("Antero Midstream" or the "Company") today announced its second quarter 2026 financial and operating results.  The relevant consolidated financial statements are included in Antero Midstream's Quarterly Report on Form 10-Q for the three months ended June 30, 2026.

prnewswire.com - 2026-07-29 16:15:00

Cetera Investment Advisers grew its position in shares of Antero Midstream Corporation (NYSE: AM) by 9.9% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 867,200 shares of the pipeline company's stock after buying an additional 77,936 shares during the quarter.

defenseworld.net - 2026-07-28 03:14:24

Bessemer Group Inc. reduced its stake in Antero Midstream Corporation (NYSE: AM) by 91.2% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,112 shares of the pipeline company's stock after selling 166,796 shares during the period. Bessemer Group Inc.'s

defenseworld.net - 2026-07-26 04:37:05

DENVER, July 15, 2026 /PRNewswire/ -- Antero Midstream Corporation (NYSE: AM) ("Antero Midstream" or the "Company") today announced that the Board of Directors of Antero Midstream declared a cash dividend of $0.225 per share for the second quarter of 2026. The Company also repurchased approximately 0.4 million shares during the second quarter.

prnewswire.com - 2026-07-15 16:15:00

Carillon Eagle Mid Cap Growth Fund stocks delivered solid results in the second quarter. Top securities in the quarter were Datadog, Marvell, Vertiv, Teradyne and Macom Technology Solutions. Top securities in the quarter were Datadog, Marvell, Vertiv, Teradyne and Macom Technology Solutions.

seekingalpha.com - 2026-07-14 08:53:00

Results from Study AM-001 mark a pivotal advance through the transition to a once daily lower 400mg dose of AM enabling: Production of GMP clinical batch for Galmed's upcoming clinical trials Solidification and prolongation of Aramchol's IP protection Potential reduction in drug CoGs by ~50% Improvement in patients' convenience and compliance upon potential commercialization RAMAT-GAN, Israel, May 14, 2026 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver disease and GI oncological therapeutics, announced today major milestone results from a Phase 1 PK study in healthy subjects (Study AM-001).

prnewswire.com - 2026-05-14 07:30:00

The energy sector is the top performer this year, but investors shouldn't forget the group's attractive dividend profile.

fool.com - 2026-05-11 10:45:00

AM's Q1 revenues top estimates on strong volumes, but rising costs weigh on earnings despite robust gathering and compression growth.

zacks.com - 2026-05-04 15:45:12